KRYS
Krystal Biotech IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$7.77B
P/E Ratio
38.59
EPS
$6.84
Beta
0.54
52W High
$298.30
52W Low
$122.80
50-Day MA
$264.85
200-Day MA
$205.85
Dividend Yield
—
Profit Margin
52.60%
Forward P/E
45.05
PEG Ratio
—
About Krystal Biotech Inc
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.
Fundamentals
| Revenue (TTM) | $389.13M |
| Gross Profit (TTM) | $366.08M |
| EBITDA | $162.92M |
| Operating Margin | 41.30% |
| Return on Equity | 18.90% |
| Return on Assets | 8.44% |
| Revenue/Share (TTM) | $13.44 |
| Book Value | $41.78 |
| Price-to-Book | 6.25 |
| Price-to-Sales (TTM) | 19.97 |
| EV/Revenue | 17.49 |
| EV/EBITDA | 40.54 |
| Quarterly Earnings Growth (YoY) | 11.60% |
| Quarterly Revenue Growth (YoY) | 17.50% |
| Shares Outstanding | $29.44M |
| Float | $23.12M |
| % Insiders | 11.51% |
| % Institutions | 98.71% |
Analyst Ratings
Consensus ($314.00 target)
10
Buy1
HoldData last updated: 4/8/2026